Structured evidence table for Fructooligosaccharides Gut Microbiota Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Fructooligosaccharides Gut Microbiota Randomized Trial | Next, we integrate these fermentation and microbial-utilization features to explain the rationale for co-administration with long-chain inulin and review the available preclinical evidence. | 3 | Fujii Tadashi (2026) | 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement |
| Fructooligosaccharides Gut Microbiota Randomized Trial | These observations provide a general rationale for testing whether co-administration of 1-kestose and long-chain inulin can influence colonic substrate availability and tolerability; the available experimental evidence is discussed in. | 3 | Fujii Tadashi (2026) | 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement |
| Fructooligosaccharides Gut Microbiota Randomized Trial | Previous work showed that bacterial GH32 amino acid sequences can be grouped by phylogenetic analysis into clusters associated with distinct fructooligosaccharide-degrading profiles [].applies this framework to compare GH32 enzymes relevant to the utilization of 1-kestose and other fructans. | 3 | Fujii Tadashi (2026) | 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement |
| Fructooligosaccharides Gut Microbiota Randomized Trial | 1 2 3 The gut microbiota is increasingly recognized as a key determinant of host physiology, and dysbiosis has been linked to a broad spectrum of diseases, including gastrointestinal, metabolic, immune, and neuropsychiatric disorders []. | 3 | Fujii Tadashi (2026) | 1-Kestose as a Candidate Precision Bioactive Component: From GH32-Dependent Gut Microbiota Regulation to Human Health Enhancement |
| Fructooligosaccharides Gut Microbiota Randomized Trial | Introduction Metabolic dysfunction-associated steatotic liver disease may be influenced by human gut microbiota-derived metabolites. | 4 | Finazzi M (2026) | Fructooligosaccharides-driven metabolism of a defined <i>Lactobacillus</i> probiotic consortium modulates hepatic lipid accumulation in a reductionist <i>in vitro</i> gut microbiota-liver interaction model. |
| Fructooligosaccharides Gut Microbiota Randomized Trial | Fructooligosaccharides (FOS) and probiotic Lactobacillus species have been reported to be associated with metabolic improvements. | 4 | Finazzi M (2026) | Fructooligosaccharides-driven metabolism of a defined <i>Lactobacillus</i> probiotic consortium modulates hepatic lipid accumulation in a reductionist <i>in vitro</i> gut microbiota-liver interaction model. |
| Fructooligosaccharides Gut Microbiota Randomized Trial | Treatment of steatotic HepG2 cells with these metabolites significantly reduced intracellular lipid accumulation and down-regulated Cd36 gene encoding a key fatty acid transporter involved in palmitic acid-induced steatosis. | 4 | Finazzi M (2026) | Fructooligosaccharides-driven metabolism of a defined <i>Lactobacillus</i> probiotic consortium modulates hepatic lipid accumulation in a reductionist <i>in vitro</i> gut microbiota-liver interaction model. |
Source documents